Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurofibromatosis 1 | 15 | 2025 | 42 | 2.180 |
Why?
|
| Neurofibromatosis 2 | 5 | 2025 | 13 | 0.750 |
Why?
|
| Neurofibroma, Plexiform | 5 | 2025 | 13 | 0.750 |
Why?
|
| Neurofibromatoses | 6 | 2025 | 13 | 0.710 |
Why?
|
| Neurilemmoma | 5 | 2025 | 37 | 0.560 |
Why?
|
| Pain Measurement | 3 | 2025 | 374 | 0.390 |
Why?
|
| Bevacizumab | 3 | 2025 | 256 | 0.390 |
Why?
|
| Fatty Acids | 5 | 1998 | 145 | 0.390 |
Why?
|
| Reye Syndrome | 8 | 1991 | 16 | 0.380 |
Why?
|
| Skin Neoplasms | 5 | 2025 | 620 | 0.350 |
Why?
|
| Neuroma, Acoustic | 2 | 2023 | 19 | 0.350 |
Why?
|
| Dicarboxylic Acids | 7 | 1991 | 24 | 0.330 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2025 | 283 | 0.330 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2025 | 291 | 0.320 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 1103 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2025 | 190 | 0.310 |
Why?
|
| Child | 23 | 2025 | 7361 | 0.300 |
Why?
|
| Quality of Life | 6 | 2025 | 1783 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2021 | 94 | 0.250 |
Why?
|
| Nervous System Neoplasms | 1 | 2006 | 10 | 0.240 |
Why?
|
| Meningioma | 2 | 2025 | 62 | 0.230 |
Why?
|
| Adolescent | 17 | 2025 | 9611 | 0.230 |
Why?
|
| Meningeal Neoplasms | 2 | 2025 | 69 | 0.230 |
Why?
|
| Cancer Pain | 1 | 2025 | 5 | 0.230 |
Why?
|
| Pain | 2 | 2025 | 415 | 0.210 |
Why?
|
| Hearing Loss | 1 | 2023 | 64 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 223 | 0.190 |
Why?
|
| Self Report | 2 | 2021 | 329 | 0.180 |
Why?
|
| Communication | 1 | 2025 | 434 | 0.180 |
Why?
|
| Young Adult | 10 | 2025 | 6936 | 0.180 |
Why?
|
| Aspirin | 4 | 1993 | 167 | 0.170 |
Why?
|
| Diphenylamine | 1 | 2021 | 5 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2019 | 184 | 0.160 |
Why?
|
| Lovastatin | 2 | 2019 | 28 | 0.160 |
Why?
|
| Child, Preschool | 11 | 2020 | 3833 | 0.160 |
Why?
|
| Male | 26 | 2025 | 44576 | 0.160 |
Why?
|
| Dura Mater | 1 | 2020 | 45 | 0.150 |
Why?
|
| Benzamides | 1 | 2021 | 246 | 0.150 |
Why?
|
| Humans | 41 | 2025 | 93598 | 0.150 |
Why?
|
| Consensus | 2 | 2013 | 368 | 0.150 |
Why?
|
| Executive Function | 2 | 2019 | 103 | 0.150 |
Why?
|
| Neurofibromin 1 | 2 | 2015 | 8 | 0.150 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 88 | 0.150 |
Why?
|
| Adult | 16 | 2025 | 27947 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 146 | 0.140 |
Why?
|
| Ammonia | 3 | 1995 | 35 | 0.140 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 1998 | 27 | 0.130 |
Why?
|
| Mitochondria, Liver | 2 | 1989 | 29 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 603 | 0.120 |
Why?
|
| Carnitine | 2 | 1993 | 14 | 0.120 |
Why?
|
| Gene Deletion | 1 | 1997 | 351 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 327 | 0.120 |
Why?
|
| Female | 20 | 2025 | 48772 | 0.120 |
Why?
|
| Infant | 9 | 2020 | 3220 | 0.120 |
Why?
|
| Noonan Syndrome | 1 | 2015 | 7 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2016 | 171 | 0.110 |
Why?
|
| Brain | 3 | 1998 | 2375 | 0.110 |
Why?
|
| Oxidation-Reduction | 6 | 1998 | 410 | 0.110 |
Why?
|
| Liver | 4 | 1998 | 1207 | 0.110 |
Why?
|
| Receptors, Serotonin | 1 | 1995 | 34 | 0.110 |
Why?
|
| Codon | 1 | 2015 | 116 | 0.110 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 2 | 1993 | 6 | 0.110 |
Why?
|
| Lipid Metabolism, Inborn Errors | 2 | 1993 | 8 | 0.110 |
Why?
|
| Phenotype | 3 | 2015 | 2543 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 331 | 0.110 |
Why?
|
| Focus Groups | 2 | 2025 | 184 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2015 | 296 | 0.100 |
Why?
|
| Valproic Acid | 1 | 1993 | 25 | 0.100 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 1993 | 5 | 0.100 |
Why?
|
| Middle Aged | 10 | 2025 | 27621 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2718 | 0.100 |
Why?
|
| Cognition | 2 | 2019 | 627 | 0.100 |
Why?
|
| Acrocephalosyndactylia | 1 | 1993 | 6 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 176 | 0.100 |
Why?
|
| Qualitative Research | 2 | 2025 | 347 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 127 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 86 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1661 | 0.100 |
Why?
|
| Mitochondria | 3 | 1993 | 612 | 0.090 |
Why?
|
| Proteins | 1 | 1997 | 800 | 0.090 |
Why?
|
| Botulism | 1 | 1992 | 6 | 0.090 |
Why?
|
| Hippocampus | 1 | 1995 | 452 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2003 | 2592 | 0.090 |
Why?
|
| Neuromuscular Junction | 1 | 1992 | 82 | 0.090 |
Why?
|
| Receptors, Drug | 1 | 1991 | 51 | 0.090 |
Why?
|
| Serum Albumin, Bovine | 1 | 1991 | 47 | 0.090 |
Why?
|
| Social Behavior | 1 | 2013 | 307 | 0.080 |
Why?
|
| Oligomycins | 1 | 1990 | 5 | 0.080 |
Why?
|
| Rutamycin | 1 | 1990 | 4 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 1992 | 223 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 457 | 0.080 |
Why?
|
| Decompression, Surgical | 2 | 2020 | 157 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
|
| Schwann Cells | 1 | 2009 | 34 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 23 | 0.080 |
Why?
|
| Neuropsychological Tests | 3 | 2019 | 543 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3837 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1998 | 1243 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 9109 | 0.070 |
Why?
|
| Albumins | 1 | 1988 | 123 | 0.070 |
Why?
|
| Rats | 5 | 1998 | 4042 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 812 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 1987 | 23 | 0.060 |
Why?
|
| Hypoxia, Brain | 1 | 1987 | 43 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 20469 | 0.060 |
Why?
|
| Cafe-au-Lait Spots | 1 | 2006 | 1 | 0.060 |
Why?
|
| Lactates | 2 | 1985 | 36 | 0.060 |
Why?
|
| Neurofibromin 2 | 1 | 2025 | 31 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2006 | 118 | 0.060 |
Why?
|
| Parent-Child Relations | 1 | 2025 | 80 | 0.050 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 166 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1731 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 236 | 0.050 |
Why?
|
| Age Factors | 2 | 2006 | 1907 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2025 | 210 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3479 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 4563 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 54 | 0.050 |
Why?
|
| Craniotomy | 1 | 2003 | 91 | 0.050 |
Why?
|
| Parents | 1 | 2025 | 292 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2009 | 1690 | 0.040 |
Why?
|
| Cell Membrane | 2 | 1995 | 661 | 0.040 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 134 | 0.040 |
Why?
|
| Cell Line | 4 | 1995 | 2458 | 0.040 |
Why?
|
| Muscles | 2 | 1992 | 184 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 51 | 0.040 |
Why?
|
| Animals | 9 | 2009 | 28041 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2020 | 25 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 1991 | 136 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 3058 | 0.040 |
Why?
|
| Psychometrics | 1 | 2021 | 337 | 0.040 |
Why?
|
| Syndrome | 2 | 1993 | 437 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2000 | 49 | 0.040 |
Why?
|
| Pseudarthrosis | 1 | 1999 | 20 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 137 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1999 | 44 | 0.040 |
Why?
|
| Intellectual Disability | 2 | 1993 | 196 | 0.040 |
Why?
|
| Cholinergic Fibers | 2 | 1990 | 23 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2000 | 239 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1990 | 490 | 0.040 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 1998 | 20 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1998 | 39 | 0.030 |
Why?
|
| Cytochrome P-450 CYP4A | 1 | 1998 | 2 | 0.030 |
Why?
|
| Pelvic Neoplasms | 1 | 1998 | 42 | 0.030 |
Why?
|
| Fatty Acids, Volatile | 1 | 1998 | 35 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 1989 | 67 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 1998 | 65 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1998 | 77 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 100 | 0.030 |
Why?
|
| Mixed Function Oxygenases | 1 | 1998 | 68 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 5406 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1790 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1998 | 278 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1998 | 361 | 0.030 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 237 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 394 | 0.030 |
Why?
|
| Dwarfism | 1 | 2015 | 13 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1913 | 0.030 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1995 | 3 | 0.030 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1995 | 14 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1951 | 0.030 |
Why?
|
| Tritium | 1 | 1995 | 113 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1995 | 69 | 0.030 |
Why?
|
| Acetates | 1 | 1995 | 58 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 7072 | 0.030 |
Why?
|
| Exotropia | 1 | 1993 | 2 | 0.030 |
Why?
|
| Thalamus | 1 | 1995 | 132 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 300 | 0.030 |
Why?
|
| Breath Tests | 1 | 1993 | 58 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1993 | 28 | 0.030 |
Why?
|
| Incidence | 1 | 1998 | 1702 | 0.030 |
Why?
|
| Keto Acids | 1 | 1993 | 5 | 0.020 |
Why?
|
| Learning | 1 | 2016 | 292 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1991 | 433 | 0.020 |
Why?
|
| Hamartoma | 1 | 1993 | 33 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 1993 | 84 | 0.020 |
Why?
|
| Hybrid Cells | 2 | 1990 | 68 | 0.020 |
Why?
|
| NIMA-Related Kinases | 1 | 2013 | 7 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1993 | 66 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 1912 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2000 | 1194 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 1993 | 120 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1993 | 304 | 0.020 |
Why?
|
| Atrophy | 1 | 1993 | 128 | 0.020 |
Why?
|
| Retinal Diseases | 1 | 1993 | 84 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 411 | 0.020 |
Why?
|
| Motor Endplate | 1 | 1992 | 29 | 0.020 |
Why?
|
| Botulinum Toxins | 1 | 1992 | 16 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1171 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 1995 | 390 | 0.020 |
Why?
|
| Synaptic Vesicles | 1 | 1992 | 39 | 0.020 |
Why?
|
| Family | 1 | 2013 | 323 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 3915 | 0.020 |
Why?
|
| Laurates | 1 | 1991 | 2 | 0.020 |
Why?
|
| Cerebellum | 1 | 1993 | 248 | 0.020 |
Why?
|
| Electromyography | 1 | 1992 | 198 | 0.020 |
Why?
|
| Palmitates | 1 | 1991 | 17 | 0.020 |
Why?
|
| Acylation | 1 | 1991 | 68 | 0.020 |
Why?
|
| Gene Expression | 1 | 1995 | 1302 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1991 | 67 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 10185 | 0.020 |
Why?
|
| Progesterone | 1 | 1991 | 113 | 0.020 |
Why?
|
| Rotenone | 1 | 1990 | 17 | 0.020 |
Why?
|
| NADH Dehydrogenase | 1 | 1990 | 22 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 1115 | 0.020 |
Why?
|
| Septal Nuclei | 1 | 1990 | 10 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 409 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1990 | 233 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 1990 | 141 | 0.020 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2009 | 1 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 1990 | 200 | 0.020 |
Why?
|
| Dinitrophenols | 1 | 1989 | 7 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 1989 | 15 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 2009 | 37 | 0.020 |
Why?
|
| Epilepsy | 1 | 1993 | 434 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 109 | 0.020 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1989 | 13 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2020 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 1989 | 58 | 0.020 |
Why?
|
| Cell Division | 1 | 1990 | 690 | 0.020 |
Why?
|
| Oleic Acid | 1 | 1988 | 15 | 0.020 |
Why?
|
| Oleic Acids | 1 | 1988 | 26 | 0.020 |
Why?
|
| Biopsy | 1 | 1992 | 1177 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7642 | 0.020 |
Why?
|
| Myocardium | 1 | 1991 | 570 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1516 | 0.020 |
Why?
|
| Intelligence | 1 | 1987 | 67 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1991 | 1354 | 0.020 |
Why?
|
| Kinetics | 1 | 1988 | 1470 | 0.010 |
Why?
|
| Chinchilla | 1 | 1985 | 4 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1985 | 26 | 0.010 |
Why?
|
| Mental Recall | 1 | 1987 | 172 | 0.010 |
Why?
|
| Ketone Bodies | 1 | 1985 | 15 | 0.010 |
Why?
|
| Uric Acid | 1 | 1985 | 137 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1985 | 198 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1985 | 238 | 0.010 |
Why?
|
| Creatinine | 1 | 1985 | 293 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1610 | 0.010 |
Why?
|
| Pyruvates | 1 | 1982 | 12 | 0.010 |
Why?
|
| Pyruvate Carboxylase | 1 | 1982 | 6 | 0.010 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 1982 | 12 | 0.010 |
Why?
|
| Acidosis | 1 | 1982 | 53 | 0.010 |
Why?
|
| Coma | 1 | 1982 | 45 | 0.010 |
Why?
|
| Mice | 3 | 1990 | 12233 | 0.010 |
Why?
|
| Hypesthesia | 1 | 2000 | 14 | 0.010 |
Why?
|
| Foot | 1 | 2000 | 56 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2000 | 57 | 0.010 |
Why?
|
| Scoliosis | 1 | 2000 | 41 | 0.010 |
Why?
|
| Back Pain | 1 | 2000 | 73 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 1999 | 11 | 0.010 |
Why?
|
| Mutation | 1 | 1990 | 4266 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1990 | 24 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 221 | 0.010 |
Why?
|
| Neurons | 1 | 1986 | 1575 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1982 | 868 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1546 | 0.010 |
Why?
|
| Databases, Factual | 1 | 1999 | 1006 | 0.010 |
Why?
|
| Neuroblastoma | 2 | 1990 | 395 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1932 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 1073 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 303 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1990 | 3430 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1999 | 2804 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1990 | 34 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 947 | 0.000 |
Why?
|
| Nerve Growth Factors | 1 | 1990 | 53 | 0.000 |
Why?
|
| Embryo, Mammalian | 1 | 1990 | 217 | 0.000 |
Why?
|
| Clone Cells | 1 | 1986 | 219 | 0.000 |
Why?
|